fashion -WSS

fashion

author：leisure time 2025-09-29 07:57:26 Page View：32

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After John Oliver segment, STAT readers share their opioid
Next article： At least 13 dead in Texas as scorching temps continue

leisure time

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Where are patients getting their prescriptions for GLP

AdobeAsanewclassofdiabetesandobesitymedicationshassoaredinpopularity,sohavetheonlineoutletsbuilttoge

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz

1:48U.S.Marineswiththe26thMarineExpeditionaryUnit(SpecialOperationsCapable)’s(MEU(SOC))MaritimeSpeci

fashion

Wikipedia

leisure time

US Marines prepare to be put on commercial ships to deter Iranian harassment in Strait of Hormuz